ACT Dry Mouth 'Immediate,' 'Moisturizing,' 'Lubricating' Claims OK In Review Appeal
Executive Summary
Council of Better Business Bureaus' advertising review appeals panel says Sanofi didn't support claiming ACT Dry Mouth Lozenges "are uniquely formulated to stimulate saliva flow” because no evidence supported uniqueness. On review of initial findings from August 2018 on GSK challenge, which markets Biotene dry mouth products, panel considered appeals by both firms.
You may also be interested in...
FDA Might Pick At Nicotine Toothpick Firm's Drug, Supplement Products
FDA warns Smart Toothpicks about selling nicotine-infused toothpicks to a minor and its online claim, "nicotine satisfaction without smoke damage to your lungs.” Escaping FDA attention so far are a dry mouth claim and a B12 formulation.
Sensodyne ProNamel TV Ad Claim's Accuracy Slips Through Cracks
NAD finds from P&G challenge that Glaxo's US consumer health business provided no evidence to support express and implied claims conveyed in two TV ads featuring animated image of a tooth surface lined with deep and narrow crevices that Sensodyne ProNamel Intensive Enamel Repair fills and heals cracked enamel.
ACT Dry Mouth Claims Get Parched In Industry Self-Regulation Review
Sanofi and GSK appeal Council of Better Business Bureaus investigative arm's recommendations from review of ACT Dry Mouth ad claims. GSK disagrees that Sanofi's could continue using a claim of "moisturizes dry mouth" and Sanofi disagrees that it did not substantiate claims that established ACT Dry Mouth, marketed with cavity prevention claims, as providing benefits similar to GSK's Biodene, which has pre-market approval for an indication of lubricating and coating the interior of the mouth and gums with moisture.